Global Atovaquone Drug Market Size, Share and Trends Analysis Report, By Type (250 mg, 500 mg, 750 mg, and Others), By Disease (Pneumocytis Jirovecii Pneumonia and Plasmodium falciparum malaria), By Distribution Channel (Hospital Pharmacies and Retail Pharmacies), Forecast (2022-2028)

The global atovaquone drug market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Atovaquone drug is prescribed in the treatment of pneumocytis jirovecii pneumonia. It type of pneumonia which is mostly affecting people who are infected with the human immunodeficiency virus. This drug is advised for use by adults and teenagers with pneumocytis jirovecii in conditions when other drugs are not prescribed. Atovaquone is a type of drug which comes under the category of antiprotozoal agents. Atovaquone stops the growth of protozoa which are responsible for pneumonia. Common symptoms which are associated with pneumocytis jirovecii pneumonia include cough, fever, and shortness of breath. This drug works as a hydroxynaphthoquinone which works on protozoa. The respiratory chain of protozoa is blocked by the atovaquone drug. This, in turn, prevents DNA synthesis which leads to protozoa death. Atovaquone drug chemical structure is closely related to ubiquinone. Their inhibitory effect is also similar to each other.
The effectiveness of the atovaquone drug over other drugs prescribed in the treatment of P falciparum malaria is expected to drive the market during the forecast period. For instance, in Jan 2021, a study was published in the Cochrane database of systematic reviews which stated that the atovaquone drug was found effective in the treatment of p falciparum malaria. The artesunate-mefloquine drug was also given to a certain number of patients who were affected by malaria. Atovaquone drug was given to another group that was taken in the study. Patients who were given atovaquone drug, it resulted in fewer treatment failures as compared to artesunate‐mefloquine drug.
Clinical trials are making possible new treatment methods with drug combinations to treat respiratory infections like COVID-19. For instance, in May 2020, Clinical trials were done at the Translational genomics research institute under which atovaquone drug along with azithromycin will be used in the treatment of covid-19. atovaquone drug is sold under the brand name mepron in the US which is prescribed in pneumonia. If this combination is compared with other combination drug trials are done, it is less likely to cause side effects such as cardiovascular ailments. Additional determining factors are analyzed in this study which may cause possible efficacy and safety.

Market Coverage
The market number available for – 2021-2028
Base year- 2021
Forecast period- 2022-2028

Segment Covered-
By Type
By Disease
By Distribution Channel

Regions Covered-
North America
Europe
Asia-Pacific
Rest of the World

Top Major Key Players:
GlaxoSmithKline plc, Glenmark Pharmaceuticals Ltd., and Lupin Ltd., among others.

Key questions addressed by the report
What is the market growth rate?
Which segment and region dominate the market in the base year?
Which segment and region will project the fastest growth in the market?
How has COVID-19 impacted the market?
Deviation from the pre-COVID-19 forecast
Most affected region and segment
Who is the leader in the market?
How players are addressing challenges to sustain growth?
Where is the investment opportunity?

Global Atovaquone Drug Market Report by Segment
By Type
250 mg
500 mg
750 mg
Others

By Disease
Pneumocytis Jirovecii Pneumonia
Plasmodium Falciparum Malaria

By Distribution Channel
Hospital Pharmacies
Retail Pharmacies